Login to Your Account



Patient death in hemophilia trial raises new questions on fitusiran

By Marie Powers
News Editor

Thursday, September 7, 2017

Alnylam Pharmaceuticals Inc. suspended dosing in ongoing studies of fitusiran following the report of a fatal thrombotic event in a patient with hemophilia A without inhibitors that occurred during the therapy's phase II open-label extension (OLE) study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription